On the stock market since 2000, it operates in the world of health and science. It has 142 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 4% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
There is $6.2M in the vault; even if every debt were paid off, $6.2M would remain.
It pays out $2.86 per share each year — regular cash for whoever holds the stock.
A loss of $258K against $18.3M in annual sales. And on top of that, sales fell from the year before.
This stock swings about 1,696,040.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, PDRX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PDRX is a small company that closed last year at a loss. The road back to profit runs through spending discipline.